Skip to main content
. 2023 Sep 6;9(3):e003027. doi: 10.1136/rmdopen-2023-003027

Figure 2.

Figure 2

Patients with RA initiating TNFi as first ever biological DMARD in Swedish, Danish and Norwegian treatment cohorts. Proportion reaching remission at 0, 3, 6 and 12 months according to six outcome definitions. ACR, American Congress of Rheumatology; ARCTIC, Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen; DANBIO, Danish Registry for Biologic Therapies in Rheumatology; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; DRB, Danish Rheumatologic Biobank; NOR-VEAC, Norwegian Very Early Arthritic Clinic; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index; SJC28, swollen 28 joint count; SRQ, Swedish Rheumatology Quality; ULRABIT, ULtrasound in Rheumatoid Arthritis patients starting BIologic Treatment; VAS, Visual Analogue Scale.